Ildong Pharmaceutical will conduct an additional round of Phase 1 clinical trial for its proprietary new drug candidate, 'ID110521156,' for the treatment of type 2 diabetes.

The drug, by the development code ID110521156, is an oral new drug targeting type 2 diabetes and obesity.

On August 20th, the Ministry of Food and Drug Safety (MFDS) approved a 'Randomized, double-blind, placebo-controlled, multiple-ascending oral dose Phase 1 study of ID110521156 in healthy adults to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of the drug,' which has been submitted by Unovia.

Unovia is an independent company established through a simp